Etanercept in Alzheimer disease: A randomized, placebo-controlled, double-blind, phase 2 trial

No abstract is available for this paper.

• Publication year

  2015

• Venue

  Neurology

• Publication date

  2015-12-08

• Fields of study

  Medicine

• Identifiers
  DOI 10.1212/WNL.0000000000002206PMID 26644054PMCID PMC5028322
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Etanercept in Alzheimer disease: A randomized, placebo-controlled, double-blind, phase 2 trial

  2015cited by this paper
• Ankylosing Spondylitis and Rheumatoid Arthritis: Serum Levels of TNF-α and Its Soluble Receptors during the Course of Therapy with Etanercept and Infliximab

  2014cited by this paper
• Microglial priming in neurodegenerative disease

  2014cited by this paper
• The size of a pilot study for a clinical trial should be calculated in relation to considerations of precision and efficiency.

  2012cited by this paper
• Brain inflammation is induced by co-morbidities and risk factors for stroke

  2011cited by this paper
• Proinflammatory cytokines, sickness behavior, and Alzheimer disease

  2011cited by this paper
• Determining the minimum clinically important differences for outcomes in the DOMINO trial

  2011cited by this paper
• Systemic inflammation and disease progression in Alzheimer disease

  2009cited by this paper
• Rapid intracerebroventricular delivery of Cu-DOTA-etanercept after peripheral administration demonstrated by PET imaging

  2009cited by this paper
• Systemic infections and inflammation affect chronic neurodegeneration

  2007cited by this paper
• Study of etanercept, a tumor necrosis factor-alpha inhibitor, in recurrent ovarian cancer.

  2005cited by this paper
• Central and Systemic Endotoxin Challenges Exacerbate the Local Inflammatory Response and Increase Neuronal Death during Chronic Neurodegeneration

  2005cited by this paper
• Validity of current clinical criteria for Alzheimer's disease, vascular dementia and dementia with Lewy bodies

  1999cited by this paper
• Clinico‐Neuropathological Correlation of Alzheimer's Disease in a Community‐Based Case Series

  1999cited by this paper
• Assessment of activities of daily living in dementia: development of the Bristol Activities of Daily Living Scale.

  1996cited by this paper
• On the use of a pilot sample for sample size determination.

  1995cited by this paper
• Cerebral blood flow in dementia.

  1975cited by this paper

• Development of potent humanized TNFα inhibitory nanobodies for therapeutic applications in TNFα-mediated diseases

  2025cites this paper
• Targeting Neuroinflammation in Synaptic Dysfunction: Translational Pharmacology for Neurodegenerative and Neuropsychiatric Disorders

  2025cites this paper
• Rubiadin Alleviates Alzheimer's Disease Pathology via NF-κB Pathway Regulation.

  2025cites this paper
• Inflammation associated microglial expansion disrupts hippocampal glial network communication, driving postoperative neurocognitive impairment

  2025cites this paper
• Neurodegeneration and aging: pathophysiology, diagnosis, and therapeutic targets

  2025influential citation
• Assessing the repurposing potential of disease-modifying antirheumatic drug targets to reduce Alzheimer's disease risk: a pQTL-based Mendelian randomization and colocalization analysis

  2025cites this paper
• The Importance of TNF-α Signaling – Potential Risk Factor in Neurodegenerative and Cardiovascular Diseases

  2025cites this paper
• Divergent disruptive effects of soluble recombinant tau assemblies on synaptic plasticity in vivo

  2025cites this paper
• Association between disease-modifying antirheumatic drugs for rheumatoid arthritis and risk of incident dementia: a systematic review with meta-analysis

  2024cites this paper
• Elucidation of the inhibitory effects of Jiedu Yizhi formula on neuronal apoptosis in the treatment of Alzheimer’s disease based on network pharmacology and in vivo experiments

  2024cites this paper
• An insight into the concept of neuroinflammation and neurodegeneration in Alzheimer’s disease: targeting molecular approach Nrf2, NF-κB, and CREB

  2024cites this paper
• Skin-brain axis in Alzheimer's disease - Pathologic, diagnostic, and therapeutic implications: A Hypothetical Review

  2024cites this paper
• Association of Tumor Necrosis Factor-α Inhibitors with Incident Dementia: Analysis Based on Population-Based Cohort Studies

  2024cites this paper
• Disease-Modifying Antirheumatic Drugs and Dementia Prevention: A Systematic Review of Observational Evidence in Rheumatoid Arthritis

  2024cites this paper
• Leveraging generative AI to prioritize drug repurposing candidates for Alzheimer’s disease with real-world clinical validation

  2024cites this paper
• Neuroinflammation Biomarkers in the AT(N) Framework Across the Alzheimer’s Disease Continuum

  2023cites this paper
• Rheumatoid arthritis is a protective factor against Alzheimer’s disease: a bidirectional two-sample Mendelian randomization study

  2023cites this paper
• Diverse signaling mechanisms and heterogeneity of astrocyte reactivity in Alzheimer's disease

  2023cites this paper
• Inflammation, Autoimmunity and Neurodegenerative Diseases, Therapeutics and Beyond

  2023cites this paper
• Overlapping Neuroimmune Mechanisms and Therapeutic Targets in Neurodegenerative Disorders

  2023cites this paper
• Copper metabolism-related Genes in entorhinal cortex for Alzheimer's disease

  2023cites this paper
• Adipose tissue as a therapeutic target for vascular damage in Alzheimer's disease

  2023cites this paper
• Signaling pathways in macrophages: molecular mechanisms and therapeutic targets

  2023cites this paper
• Alzheimer’s Disease-Related Epigenetic Changes: Novel Therapeutic Targets

  2023cites this paper
• Molecular and environmental contributors to neurological complications in sickle cell disease

  2023cites this paper
• The TNFR1 antagonist Atrosimab reduces neuronal loss, glial activation and memory deficits in an acute mouse model of neurodegeneration

  2023cites this paper
• Alzheimer’s disease and neuroinflammation: will new drugs in clinical trials pave the way to a multi-target therapy?

  2023cites this paper
• The effect of the tumour necrosis factor-alpha-inhibitor etanercept on microglial activation patients with mild cognitive impairment—a PET study

  2023cites this paper
• Immunotherapy for Alzheimer’s disease: targeting β-amyloid and beyond

  2022cites this paper
• Synaptic degeneration in Alzheimer disease

  2022cites this paper
• Prevalence of cognitive impairment in patients with rheumatoid arthritis: a cross sectional study

  2022cites this paper
• RENEWAL: REpurposing study to find NEW compounds with Activity for Lewy body dementia—an international Delphi consensus

  2022cites this paper
• The Link between Oxidative Stress, Mitochondrial Dysfunction and Neuroinflammation in the Pathophysiology of Alzheimer’s Disease: Therapeutic Implications and Future Perspectives

  2022cites this paper
• Keep It in Mind: Assessing the Risk of Dementia in Patients With Rheumatoid Arthritis and Opportunities for Intervention

  2022cites this paper
• Efficacy and Safety of a Brain-Penetrant Biologic TNF-α Inhibitor in Aged APP/PS1 Mice

  2022cites this paper
• Immune system-wide Mendelian randomization and triangulation analyses support autoimmunity as a modifiable component in dementia-causing diseases

  2022cites this paper
• The Immune System as a Therapeutic Target for Alzheimer’s Disease

  2022cites this paper
• Symptomatic and Disease-Modifying Therapy Pipeline for Alzheimer’s Disease: Towards a Personalized Polypharmacology Patient-Centered Approach

  2022cites this paper
• Neuroinflammation in Alzheimer’s Disease: Current Progress in Molecular Signaling and Therapeutics

  2022cites this paper
• The Pivotal Role of NF-kB in the Pathogenesis and Therapeutics of Alzheimer’s Disease

  2022influential citation
• ALZT-OP1: an experimental combination regimen for the treatment of Alzheimer’s disease

  2022cites this paper
• Obesity and the Brain

  2022cites this paper
• Inhibition of the CEBPβ-NFκB interaction by nanocarrier-packaged Carnosic acid ameliorates glia-mediated neuroinflammation and improves cognitive function in an Alzheimer’s disease model

  2022cites this paper
• Disease-Modifying Therapies for Alzheimer’s Disease: More Questions than Answers

  2022cites this paper
• Cytokine signaling convergence regulates the microglial state transition in Alzheimer’s disease

  2021cites this paper
• Targeting innate immunity to protect and cure Alzheimer’s disease: opportunities and pitfalls

  2021cites this paper
• Dementia with Lewy bodies: emerging drug targets and therapeutics

  2021cites this paper
• Pro-inflammatory interleukin-6 signaling links cognitive impairments and peripheral metabolic alterations in Alzheimer’s disease

  2021cites this paper
• Targeting Impaired Antimicrobial Immunity in the Brain for the Treatment of Alzheimer’s Disease

  2021cites this paper
• New insights in drug development for Alzheimer's disease based on microglia function.

  2021cites this paper
• Immunomodulation with IL-17 and TNF-α in spondyloarthritis: focus on the eye and the central nervous system

  2021cites this paper
• NDT_A_264910 1311..1339

  2021cites this paper
• An Integrated Molecular Atlas of Alzheimer's Disease

  2021cites this paper
• On the Common Journey of Neural Cells through Ischemic Brain Injury and Alzheimer’s Disease

  2021cites this paper
• Treatment with TNF‐α inhibitors versus methotrexate and the association with dementia and Alzheimer's disease

  2021cites this paper
• Mechanisms Involved in Microglial-Interceded Alzheimer’s Disease and Nanocarrier-Based Treatment Approaches

  2021cites this paper
• No increased risk of Alzheimer’s disease among people with immune-mediated inflammatory diseases: findings from a longitudinal cohort study of U.S. older adults

  2021cites this paper
• Role of the Cholinergic Anti-Inflammatory Reflex in Central Nervous System Diseases

  2021cites this paper
• Pharmacological approaches to mitigate neuroinflammation in Alzheimer's disease.

  2020cites this paper
• Therapeutic Potential of TNF-α Inhibition for Alzheimer’s Disease Prevention

  2020cites this paper
• Reviews on New Drug Targets in Age-Related Disorders

  2020cites this paper
• Early Detection and Prevention of Alzheimer’s Disease: Role of Oxidative Markers and Natural Antioxidants

  2020cites this paper
• Genetics of Hidradenitis Suppurativa

  2020cites this paper
• Tumor Necrosis Factor (TNF) blocking agents are associated with lower risk for Alzheimer’s disease in patients with rheumatoid arthritis and psoriasis

  2020cites this paper
• Anti-amyloid-β protein agents for the treatment of Alzheimer’s disease: an update on emerging drugs

  2020cites this paper
• Management of older people during the COVID‐19 outbreak: Recommendations from an Italian experience

  2020cites this paper
• Cognitive impairment in elderly patients with rheumatic disease and the effect of disease-modifying anti-rheumatic drugs

  2020cites this paper
• A multitude of signaling pathways associated with Alzheimer's disease and their roles in AD pathogenesis and therapy

  2020cites this paper
• University of Groningen Targeting TNFR 2 as a novel therapeutic strategy for Alzheimer ' s disease

  2019cites this paper
• Developing Effective Alzheimer’s Disease Therapies: Clinical Experience and Future Directions

  2019cites this paper
• Pharmacological inhibition of APP processing and knock-down of APP in primary human macrophages impairs the secretion of cytokines

  2019cites this paper
• Insulin Resistance as a Shared Pathogenic Mechanism Between Depression and Type 2 Diabetes

  2019cites this paper
• Targeting TNFR2 as a Novel Therapeutic Strategy for Alzheimer’s Disease

  2019cites this paper
• Safety, tolerability, pharmacokinetics, and pharmacodynamics of low dose lysergic acid diethylamide (LSD) in healthy older volunteers

  2019cites this paper
• Exploiting microglial and peripheral immune cell crosstalk to treat Alzheimer’s disease

  2019cites this paper
• Active Fraction Combination from Liuwei Dihuang Decoction (LW-AFC) Alleviated the LPS-Induced Long-Term Potentiation Impairment and Glial Cells Activation in Hippocampus of Mice by Modulating Immune Responses

  2019cites this paper
• Therapeutic implications of how TNF links apolipoprotein E, phosphorylated tau, α‐synuclein, amyloid‐β and insulin resistance in neurodegenerative diseases

  2018cites this paper
• The influence of TNF inhibitors on dementia incidence in patients with rheumatoid arthritis; an analysis from the BSRBR‐RA

  2018cites this paper
• Cytokine alterations and cognitive impairment in major depressive disorder: From putative mechanisms to novel treatment targets.

  2018cites this paper
• A New Venue of TNF Targeting

  2018cites this paper
• Precision pharmacology for Alzheimer's disease.

  2018cites this paper
• Erratum

  2018cites this paper
• Targeting Neuroin fl ammation as a Therapeutic Strategy for Alzheimer ’ s Disease : Mechanisms , Drug Candidates , and New Opportunities

  2018cites this paper
• TNF alpha inhibitors in Alzheimer's disease: A systematic review

  2018influential citation
• The Place of PET to Assess New Therapeutic Effectiveness in Neurodegenerative Diseases

  2018cites this paper
• Molecular Targets for PET Imaging of Activated Microglia: The Current Situation and Future Expectations

  2017cites this paper
• Characterizing the “POAGome”: A bioinformatics‐driven approach to primary open‐angle glaucoma

  2017influential citation
• Astrocytes and synaptic plasticity in health and disease

  2017cites this paper
• Peripheral administration of the soluble TNF inhibitor XPro1595 modifies brain immune cell profiles, decreases beta-amyloid plaque load, and rescues impaired long-term potentiation in 5xFAD mice.

  2017cites this paper
• Rheumatoid arthritis and risk for Alzheimer’s disease: a systematic review and meta-analysis and a Mendelian Randomization study

  2017cites this paper
• Tumor necrosis factor α Inhibition for Alzheimer’s Disease

  2017cites this paper
• Immunomodulatory and neuroprotective approaches including human mesenchymal precursor cell transplantation for spinal cord injury repair

  2017cites this paper
• List of excluded studies and reasons for exclusion

  2017cites this paper
• Alzheimer's Disease: The Role of Microglia in Brain Homeostasis and Proteopathy

  2017cites this paper
• Nutritional and Pharmacological Strategies to Regulate Microglial Polarization in Cognitive Aging and Alzheimer’s Disease

  2017cites this paper
• Etanercept protects rat cardiomyocytes against hypertrophy by regulating inflammatory cytokines secretion and cell apoptosis

  2017cites this paper
• TNFα affects CREB-mediated neuroprotective signaling pathways of synaptic plasticity in neurons as revealed by proteomics and phospho-proteomics

  2017cites this paper
• Targeting neuroinflammation in Alzheimer’s disease: evidence for NSAIDs and novel therapeutics

  2017cites this paper
• Targeting Neuroinflammation to Treat Alzheimer’s Disease

  2017cites this paper
• TREM2 expression in the human brain: a marker of monocyte recruitment?

  2017cites this paper